BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST

摘要

Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.